Core Insights - The company focuses on its main business and enhances its allergen product pipeline, particularly in the field of allergic disease diagnosis and treatment [1] Financial Performance - The company achieved operating revenue of 484 million yuan, an increase of 12.81% compared to the same period last year [1] - The net profit attributable to shareholders was 177 million yuan, reflecting an 18.61% increase year-on-year [1] Product Sales Performance - Sales revenue from dust mite drops reached approximately 454.66 million yuan, up by 10.51% year-on-year [1] - Sales revenue from Artemisia pollen sublingual drops was about 21.02 million yuan, showing a significant increase of 71.37% compared to the previous year [1] - Sales revenue from skin prick solution amounted to approximately 6.33 million yuan, marking a substantial growth of 104.38% year-on-year [1] - The rapid growth in sales of Artemisia pollen sublingual drops and skin prick solution is primarily attributed to the company's increased marketing efforts for these products [1]
我武生物(300357.SZ):上半年净利润1.77亿元 同比增长18.61%